Scarica l'app Stockscreener
125.39
2.45%
-3.2954
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$128.69
Aprire:
$129.365
Volume 24 ore:
413.66K
Relative Volume:
0.29
Capitalizzazione di mercato:
$18.39B
Reddito:
$9.82B
Utile/perdita netta:
$1.48B
Rapporto P/E:
12.38
EPS:
10.13
Flusso di cassa netto:
$2.30B
1 W Prestazione:
-6.46%
1M Prestazione:
-0.79%
6M Prestazione:
-10.68%
1 anno Prestazione:
-44.27%
Intervallo 1D:
$125.24
$129.58
Intervallo di 1 settimana:
$125.24
$134.21
Portata 52W:
$110.03
$236.48
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Confronta BIIB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
125.50 | 19.83B | 9.82B | 1.48B | 2.30B | 10.13 |
|
LLY
Lilly Eli Co
|
770.10 | 709.79B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
163.91 | 379.41B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
189.18 | 344.45B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
114.70 | 244.38B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
64.28 | 315.52B | 43.59B | 15.04B | 10.74B | 3.3766 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
What drives Biogen Inc. stock priceDynamic portfolio growth - Jammu Links News
Here's What To Expect From Biogen's Next Earnings Report - Barchart.com
Samsung Bioepis Partners with Harrow to Expand US Ophthalmology Market - Asia Business Outlook
Edgestream Partners L.P. Sells 3,285 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Leo Wealth LLC - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Acquires 736,301 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Global Motor Neuron Disease Treatment Market to Exhibit Substantial Growth at a CAGR of ~6% by 2032 | DelveInsight - GlobeNewswire
Biogen’s Innovative Approach to SMA Treatment: The PIERRE-PK Study - TipRanks
Biogen’s Spinraza Study: Real-World Insights and Market Impact - TipRanks
Biogen’s New Study on MS Drug Vumerity: Key Insights for Investors - TipRanks
Biogen’s Promising Phase 3 Trial: Felzartamab for Kidney Transplant Rejection - TipRanks
Düsseldorf court to hear Tecfidera PI appeal as Biogen fights to stop generics - JUVE Patent
What is William Blair's Estimate for Biogen Q3 Earnings? - MarketBeat
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Business Wire
Biogen Inc. (NASDAQ:BIIB) Stock Position Reduced by Massachusetts Financial Services Co. MA - MarketBeat
Wedbush Forecasts Biogen's Q2 Earnings (NASDAQ:BIIB) - MarketBeat
Cwm LLC Grows Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
New York State Common Retirement Fund Acquires 20,130 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Alps Advisors Inc. Purchases Shares of 2,500 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Cerity Partners LLC Increases Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Biogen Executive Makes Significant Stock Sale - TipRanks
Insider Selling: Biogen Inc. (NASDAQ:BIIB) Insider Sells 2,223 Shares of Stock - MarketBeat
Brown Advisory Inc. Trims Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Phase 3 Study on Felzartamab for IgA Nephropathy: Market Implications - TipRanks
Wedbush Forecasts Biogen's Q3 Earnings (NASDAQ:BIIB) - MarketBeat
Orphan Drugs Market Expansion Fueled by Rare Disease Research - openPR.com
William Blair Has Optimistic Outlook of Biogen Q2 Earnings - MarketBeat
Cognition Enhancing Drugs Market CAGR 5.6 % innovations and key - openPR.com
State of Michigan Retirement System Has $5.43 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
FY2025 EPS Estimates for Biogen Reduced by Leerink Partnrs - MarketBeat
Erythromelalgia Treatment Market Growing with Rare Disease - openPR.com
Wedbush Raises Price Target on Biogen to $129 From $121, Keeps Neutral Rating - MarketScreener
Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors - GlobeNewswire Inc.
Biogen’s New Study on Omaveloxolone for Young FA Patients: Market Insights - TipRanks
SMN1 Gene Replacement Market 2025: Increasing SMA Population - openPR.com
Spinocerebellar Ataxias Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc, Biohaven Pharma - Barchart.com
Bank of New York Mellon Corp Sells 20,984 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Holdings Cut by Greenleaf Trust - MarketBeat
M&T Bank Corp Has $1.68 Million Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
When (BIIB) Moves Investors should Listen - news.stocktradersdaily.com
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Nisa Investment Advisors LLC - MarketBeat
Banque Pictet & Cie SA Purchases 4,780 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Gene Therapy Market to Hit US$36.55 Billion by 2032 with 19.4% CAGR | MarketsandMarkets™ - Barchart.com
HSBC Raises Price Target on Biogen to $144 From $121, Maintains Hold Rating - MarketScreener
Biogen Inc.'s (NASDAQ:BIIB) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock? - 富途牛牛
JPMorgan maintains Neutral rating on Biogen stock amid gradual Leqembi ramp - Investing.com Nigeria
Case builds for Biogen, Stoke's Dravet syndrome drug - pharmaphorum
Allspring Global Investments Holdings LLC Has $1.43 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Phase 3 Study on Felzartamab for IgA Nephropathy: A Market Game-Changer? - TipRanks
RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT - Insider Monkey
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.23%
0.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):